Nūhou

ʻO RD13-02 kahi huahana kelepona CAR-T ākea e kuhikuhi ana iā CD7 i loaʻa mai nā mea hāʻawi olakino, a ua manaʻo ʻia no ka mālama ʻana i ka leukemia/lymphoma lymphoblastic acute T-cell (T-ALL/LBL) i hoʻihoʻi ʻia a i ʻole refractory. Ua hoʻololi ʻia ke ʻano genetic e pale aku i ka fratricide, ka maʻi graft-versus-host (GvHD), a me ka host-versus-...E heluhelu hou aku»

He moho huahana GPC3 CAR T-cell autologous ʻo CT011 no ka mālama ʻana i ka hepatocellular carcinoma (HCC). Ua loaʻa iā CT011 ka ʻae ʻana o IND mai ka NMPA i ka makahiki 2019 no ka mālama ʻana i nā maʻi me ka GPC3-positive solid tumor ʻo ia ka ʻae ʻana o IND mua loa o Kina no ka CAR T-cell therapy e kūʻē i ka solid ...E heluhelu hou aku»

Ua loaʻa i kekahi polopeka kulanui Lūkini i ka hopena o kona mau makahiki kanahikukūmāhiku ka maʻi myeloma multiple holomua. Ma hope o ka hana ʻana i nā lāʻau lapaʻau he nui a me ʻelua mau hoʻi hou ʻana o ka hoʻoili ʻana o ka autologous, ua aʻo ʻo ia e pili ana i ka lāʻau lapaʻau anti-cancer hou loa ʻo CAR-T ma Kina, no laila ua hele mai ʻo ia i Kina e loaʻa i ka CAR-T cell ther...E heluhelu hou aku»

Ma Iulai 20, ua ʻae kūhelu ʻia ka New Drug Application (NDA) o pCAR-19B i hoʻomohala kūʻokoʻa ʻia e Precision Biology e ka China National Medical Products Administration (NMPA). ʻO kēia huahana ka huahana CAR-T mua no ka leukemia kamaliʻi ma Kina, i hoʻohana ʻia e mālama i nā poʻe maʻi 3-21 makahiki ...E heluhelu hou aku»

ʻO satricabtagene autoleucel（Satri-cel, CT041) he moho huahana CAR T-cell autologous e kūʻē i ka protein Claudin18.2 nona ka hiki ke lilo i mua ma ka papa honua. Hoʻopaʻa ʻo Satri-cel i nā puʻupuʻu paʻa maikaʻi ʻo Claudin18.2 me kahi manaʻo nui i ka maʻi ʻaʻai gastric/gastroesophageal junction canc...E heluhelu hou aku»

Ma ka lā 6 o Kepakemapa, 2021, ua hoʻolaha ʻo JW Therapeutics ua ʻāpono ka National Medical Products Administration (NMPA) o Kina i ka New Drug Application (NDA) no kāna huahana immunotherapy cell anti-CD19 autologous chimeric antigen receptor T (CAR-T) relmacabtagene autoloucel injection (relma-cel) ...E heluhelu hou aku»

ʻO Equecabtagene autoleucel (eque-cel), kahi lāʻau lapaʻau T-cell chimeric antigen receptor (CAR) i loaʻa mai ke kanaka, ua hōʻike i ka hiki ke mālama i ka myeloma multiple relapsed a refractory paha (R/RMM). Ma Iune 30,2023, ʻo Kina National Medical Products Admi...E heluhelu hou aku»

Ma ʻOkakopa 11, 2024, ua ʻāpono ka ʻAha Hoʻokele Huahana Lapaʻau Lahui o Kina (NMPA) i ka noi Investigational New Drug（IND） no Inaticabtagene Autoleucel (CNCT19 Injection), kahi lāʻau lapaʻau cell autologous chimeric antigen receptor (CAR)-T i hoʻolālā ʻia e CD19, e mālama i ka immunothrombocytopenia ...E heluhelu hou aku»

Ma Malaki 1, 2024, ua ʻāpono ka ʻĀina Hoʻokele Huahana Lapaʻau Lahui Kina (NMPA) i ka hoʻokuʻu ʻia ʻana o ka huahana kelepona CAR-T ʻo Zevorcabtagene AutoLeucel (Zevor-cel, CT053) no ka mālama ʻana i nā poʻe maʻi makua me ka myeloma multiple relapsed a refractory paha i holomua ma hope o 3 mau laina o ka mālama ʻana (...E heluhelu hou aku»

ʻO Clustered regularly interspaced short palindromic repeats (CRISPR) kahi ʻenehana hoʻoponopono genome hanauna ʻekolu i hoʻololi i ka honua me kāna mau hopena throughput kiʻekiʻe. Ua hoʻohana ʻia e mālama i nā maʻi olaola like ʻole a me nā maʻi. ʻO nā bacteria like ʻole...E heluhelu hou aku»

Hihia 1: Ua hele ke kāne maʻi 69 makahiki i ka haukapila no ka hoʻokolokolo ʻana ma muli o ka ʻeha o ka umauma. ʻO ka mea pōʻino, ua loaʻa iā ia ka maʻi carcinoma cell squamous low-differentiated o ka māmā ʻākau o luna. ʻAʻole hiki i ka mea maʻi ke ʻae i ke ʻoki kino. Ma hope o ke kūkākūkā loea, ʻo ka cryoablation ka hopena maikaʻi loa a...E heluhelu hou aku»

Cryoablation: "Nūhou maikaʻi" no nā maʻi me nā puʻupuʻu paʻa ma nā ʻāpana like ʻole o ke kino Ua make ka hōkū kiʻiʻoniʻoni kaulana o Hong Kong ʻo Wu MengDa i ka maʻi kanesa o ke akepaʻa, ua hoʻonāukiuki ka haʻalele ʻana o ʻAnakala Da i nā poʻe he nui i ka mihi. Ua ʻike mua ʻia ka "maʻi kanesa o ke akepaʻa" ʻo ia ke aliʻi o ke kanesa, a he 70% o ke akepaʻa ...E heluhelu hou aku»